Literature DB >> 19181932

Peptides with dual binding specificity for HLA-A2 and HLA-E are encoded by alternatively spliced isoforms of the antioxidant enzyme peroxiredoxin 5.

Marialuisa Sensi1, Gabriella Pietra, Alessandra Molla, Gabriella Nicolini, Claudia Vegetti, Ilaria Bersani, Enrico Millo, Elizabeth Weiss, Lorenzo Moretta, Maria Cristina Mingari, Andrea Anichini.   

Abstract

Peptides with dual binding specificity for classical HLA class I and non-classical HLA-E molecules have been identified in virus-encoded proteins, but not in cellular proteins from normal or neoplastic cells. Expression screening of a melanoma cDNA library with a CTL clone recognizing an HLA-A2-restricted tumor-specific epitope encoded by mutant peroxiredoxin 5 (Prdx5), a stress-inducible peroxidase, led to the identification of two alternatively spliced isoforms of the same gene. These isoforms, which lack the catalytic cysteine fundamental for enzymatic activity, showed widespread expression in neoplastic and normal tissues but were unstable at the protein level, being detectable, following transient transfection, only after lactacystin treatment to inhibit proteasomal degradation. Isoform-specific sequences which formed, respectively, as result of exon 1 splicing to either exon 3 or 4, encoded two distinct nonapeptides (AMAPIKTHL and AMAPIKVRL, not present in the full-length protein) with anchor residues for HLA-A2 and HLA-E molecules and able to stabilize HLA-A2 and HLA-E cell surface expression. HLA-E+ targets, loaded with these peptides, were not recognized by NK cells expressing CD94/NKG2A inhibitory or CD94/NKG2C activatory receptors. However, both peptides were recognized, although with low avidity, by HLA-E-restricted CD8+ CTL. The nonapeptide AMAPIKVRL was used to elicit HLA-A2-restricted CTL clones that killed peptide-pulsed lymphoblastoid cell lines and melanoma cells expressing the corresponding Prdx5 isoform. Our results suggest that alternatively spliced isoforms of Prdx5, through the generation of HLA-E- and HLA-A2-restricted peptides may be part of immune-mediated stress response contributing to the detection and elimination of damaged normal or neoplastic cells.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19181932     DOI: 10.1093/intimm/dxn141

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  10 in total

1.  Modulation of MHC class I surface expression in B16F10 melanoma cells by methylseleninic acid.

Authors:  Claudia Lennicke; Jette Rahn; Jürgen Bukur; Falko Hochgräfe; Ludger A Wessjohann; Rudolf Lichtenfels; Barbara Seliger
Journal:  Oncoimmunology       Date:  2016-12-21       Impact factor: 8.110

2.  Identification of HLA-E Binding Mycobacterium tuberculosis-Derived Epitopes through Improved Prediction Models.

Authors:  Paula Ruibal; Kees L M C Franken; Krista E van Meijgaarden; Marjolein van Wolfswinkel; Ian Derksen; Ferenc A Scheeren; George M C Janssen; Peter A van Veelen; Charlotte Sarfas; Andrew D White; Sally A Sharpe; Fabrizio Palmieri; Linda Petrone; Delia Goletti; Thomas Abeel; Tom H M Ottenhoff; Simone A Joosten
Journal:  J Immunol       Date:  2022-09-12       Impact factor: 5.426

Review 3.  The emerging role of HLA-E-restricted CD8+ T lymphocytes in the adaptive immune response to pathogens and tumors.

Authors:  Gabriella Pietra; Chiara Romagnani; Claudia Manzini; Lorenzo Moretta; Maria Cristina Mingari
Journal:  J Biomed Biotechnol       Date:  2010-06-22

Review 4.  HLA-E: a novel player for histocompatibility.

Authors:  Thomas Kraemer; Rainer Blasczyk; Christina Bade-Doeding
Journal:  J Immunol Res       Date:  2014-10-20       Impact factor: 4.818

5.  Selinexor Enhances NK Cell Activation Against Malignant B Cells via Downregulation of HLA-E.

Authors:  Jack G Fisher; Christopher J Walker; Amber Dp Doyle; Peter Wm Johnson; Francesco Forconi; Mark S Cragg; Yosef Landesman; Salim I Khakoo; Matthew D Blunt
Journal:  Front Oncol       Date:  2021-12-01       Impact factor: 6.244

Review 6.  Four Faces of Cell-Surface HLA Class-I: Their Antigenic and Immunogenic Divergence Generating Novel Targets for Vaccines.

Authors:  Mepur H Ravindranath; Narendranath M Ravindranath; Senthamil R Selvan; Edward J Filippone; Carly J Amato-Menker; Fatiha El Hilali
Journal:  Vaccines (Basel)       Date:  2022-02-21

7.  Mouse and human antibodies bind HLA-E-leader peptide complexes and enhance NK cell cytotoxicity.

Authors:  Dapeng Li; Simon Brackenridge; Lucy C Walters; Olivia Swanson; Karl Harlos; Daniel Rozbesky; Derek W Cain; Kevin Wiehe; Richard M Scearce; Maggie Barr; Zekun Mu; Robert Parks; Max Quastel; Robert J Edwards; Yunfei Wang; Wes Rountree; Kevin O Saunders; Guido Ferrari; Persephone Borrow; E Yvonne Jones; S Munir Alam; Mihai L Azoitei; Geraldine M Gillespie; Andrew J McMichael; Barton F Haynes
Journal:  Commun Biol       Date:  2022-03-28

8.  HLA-E-restricted cross-recognition of allogeneic endothelial cells by CMV-associated CD8 T cells: a potential risk factor following transplantation.

Authors:  Mathilde Allard; Pierre Tonnerre; Steven Nedellec; Romain Oger; Alexis Morice; Yannick Guilloux; Elisabeth Houssaint; Béatrice Charreau; Nadine Gervois
Journal:  PLoS One       Date:  2012-11-30       Impact factor: 3.240

9.  Proteomic Analysis of the Vitreous following Experimental Retinal Detachment in Rabbits.

Authors:  Nakul Mandal; Geoffrey P Lewis; Steven K Fisher; Steffen Heegaard; Jan U Prause; Morten la Cour; Henrik Vorum; Bent Honoré
Journal:  J Ophthalmol       Date:  2015-11-18       Impact factor: 1.909

Review 10.  What the HLA-I!-Classical and Non-classical HLA Class I and Their Potential Roles in Type 1 Diabetes.

Authors:  Rebecca C Wyatt; Giacomo Lanzoni; Mark A Russell; Ivan Gerling; Sarah J Richardson
Journal:  Curr Diab Rep       Date:  2019-12-09       Impact factor: 4.810

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.